Arzneiwerk AG (TLIK) Fair Value & Analysis
Healthcare · DE · Market cap €3.8M
Fair value as of: Jul 17, 2026
From 2 valuation models · updated today
Fair value updated Jul 17, 2026, revised from €59.99 to €0.2256 (−99.6%) since Jun 24, 2026. Share price −20.8% over the past month.
Price vs Fair Value (12 months)
12‑month range €0.0005 – €0.7250 · fair‑value band €0.1126 – €0.3435 · the €0.2060 price screens below the €0.2256 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Arzneiwerk AG (TLIK) currently trades at €0.2060, while our model-based Fair Value estimate is €0.2256, implying the stock looks roughly 9.5% fairly valued today. We read business quality at 28/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at €239K. It earns a return on equity of -96.8%. Fundamentals as of Jul 17, 2026
Our scenario range runs from €0.1126 (bear case) to €0.3435 (bull case); at €0.2060, the current price sits within that range. The share trades about 72% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 16% fair-value upside, at 10%, TLIK screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
Arzneiwerk AG VIDA engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe. The company was formerly known as TELES Aktiengesellschaft and changed its name to Arzneiwerk AG VIDA in July 2024. The company was incorporated in 1996 and is based in Berlin, Germany.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Arzneiwerk AG reported revenue of €658K in FY2024 versus €2.8M in FY2020, a compound −30.5%/yr. Reported net income was −€835K in FY2024.
Is TLIK fairly valued? → Check now
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$1,022 | R$1,243 | +22% |
| Cencora, Inc COR | $271.28 | $175.74 | -35% |
| Cardinal Health, Inc CAH | $222.74 | $141.77 | -36% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.7800 | -67% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥56.73 | +255% |
| Henry Schein, Inc HSIC | $76.30 | $53.31 | -30% |
| Galenica AG GALNF | $115.00 | $84.59 | -26% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.69 | ¥25.18 | +16% |
| Medipal Holdings MEPDF | $18.35 | $23.62 | +29% |
| Jointown Pharmaceutical Group 600998 | ¥4.79 | ¥11.56 | +141% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Arzneiwerk AG (TLIK) undervalued?
What is the fair value of TLIK?
What is the quality score of TLIK?
What is the revenue of Arzneiwerk AG (TLIK)?
What is the net profit margin of TLIK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Arzneiwerk AG analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.